Ligand Pharmaceuticals Inc (LGND)
70.90
+0.97
(+1.39%)
USD |
NASDAQ |
May 01, 13:52
Ligand Pharmaceuticals Cash from Operations (Quarterly): 8.065M for Dec. 31, 2023
Cash from Operations (Quarterly) Chart
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 8.065M |
| September 30, 2023 | 7.646M |
| June 30, 2023 | -0.082M |
| March 31, 2023 | 33.95M |
| December 31, 2022 | 53.47M |
| September 30, 2022 | 20.49M |
| June 30, 2022 | 11.88M |
| March 31, 2022 | 52.01M |
| December 31, 2021 | 27.64M |
| September 30, 2021 | 20.02M |
| June 30, 2021 | 20.38M |
| March 31, 2021 | 10.75M |
| December 31, 2020 | 0.537M |
| September 30, 2020 | 12.74M |
| June 30, 2020 | 24.38M |
| March 31, 2020 | 16.92M |
| December 31, 2019 | -7.339M |
| September 30, 2019 | -6.197M |
| June 30, 2019 | -61.06M |
| March 31, 2019 | 45.26M |
| December 31, 2018 | 32.57M |
| September 30, 2018 | 27.08M |
| June 30, 2018 | 73.64M |
| March 31, 2018 | 60.76M |
| December 31, 2017 | 31.31M |
| Date | Value |
|---|---|
| September 30, 2017 | 27.65M |
| June 30, 2017 | 10.39M |
| March 31, 2017 | 19.22M |
| December 31, 2016 | 18.72M |
| September 30, 2016 | 18.52M |
| June 30, 2016 | 10.37M |
| March 31, 2016 | 13.11M |
| December 31, 2015 | 13.66M |
| September 30, 2015 | 10.44M |
| June 30, 2015 | 10.05M |
| March 31, 2015 | 7.579M |
| December 31, 2014 | 10.25M |
| September 30, 2014 | 3.735M |
| June 30, 2014 | 4.008M |
| March 31, 2014 | 2.577M |
| December 31, 2013 | 12.03M |
| September 30, 2013 | -0.359M |
| June 30, 2013 | 6.937M |
| March 31, 2013 | 2.078M |
| December 31, 2012 | 2.172M |
| September 30, 2012 | -0.91M |
| June 30, 2012 | -0.732M |
| March 31, 2012 | -0.369M |
| December 31, 2011 | 7.017M |
| September 30, 2011 | -1.055M |
Cash From Operations Definition
Cash flow from operations is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall operating activities of the company. A few examples of operating activities include change in receivables, change in inventories, and changes in current assets.
Cash from Operations (Quarterly) Range, Past 5 Years
-61.06M
Minimum
Jun 2019
53.47M
Maximum
Dec 2022
12.96M
Average
12.74M
Median
Sep 2020
Cash from Operations (Quarterly) Benchmarks
| ANI Pharmaceuticals Inc | 44.74M |
| ADMA Biologics Inc | 17.60M |
| Viking Therapeutics Inc | -6.134M |
| Corcept Therapeutics Inc | 5.887M |
| Palatin Technologies Inc | -10.48M |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | -10.28M |
| Cash from Financing (Quarterly) | 5.315M |
| Free Cash Flow | -4.272M |
| Free Cash Flow Per Share (Quarterly) | -2.415 |
| Free Cash Flow to Equity (Quarterly) | -42.68M |
| Free Cash Flow to Firm (Quarterly) | -42.68M |
| Free Cash Flow Yield | -0.34% |